2018 Q4 Form 10-Q Financial Statement
#000114420418058518 Filed on November 09, 2018
Income Statement
| Concept | 2018 Q4 | 2018 Q3 | 2018 Q2 |
|---|---|---|---|
| Revenue | $8.991M | $5.173M | $6.815M |
| YoY Change | 19.2% | 105.28% | 54.75% |
| Cost Of Revenue | $1.580M | $1.410M | $1.668M |
| YoY Change | -12.71% | 179.21% | 89.98% |
| Gross Profit | $7.410M | $3.770M | $5.147M |
| YoY Change | -105.84% | 87.1% | 45.97% |
| Gross Profit Margin | 82.42% | 72.88% | 75.52% |
| Selling, General & Admin | $14.58M | $12.18M | $13.06M |
| YoY Change | 1.18% | -19.36% | 17.26% |
| % of Gross Profit | 196.76% | 323.08% | 253.66% |
| Research & Development | $25.05M | $19.79M | $1.000K |
| YoY Change | 73.84% | -99.94% | |
| % of Gross Profit | 338.06% | 524.93% | 0.02% |
| Depreciation & Amortization | $740.0K | $550.0K | $440.0K |
| YoY Change | -161.67% | 175.0% | 144.44% |
| % of Gross Profit | 9.99% | 14.59% | 8.55% |
| Operating Expenses | $39.63M | $88.58M | $88.43M |
| YoY Change | -135.89% | 11.44% | 19.68% |
| Operating Profit | -$41.21M | -$33.38M | -$32.21M |
| YoY Change | 34.59% | 4.97% | 26.35% |
| Interest Expense | -$3.220M | $2.228M | $2.144M |
| YoY Change | -55.03% | -30.81% | 55.36% |
| % of Operating Profit | |||
| Other Income/Expense, Net | -$2.754M | -$9.681M | |
| YoY Change | -25.65% | -4067.62% | |
| Pretax Income | -$34.63M | -$27.64M | -$34.28M |
| YoY Change | 46.12% | -23.86% | 49.37% |
| Income Tax | $944.0K | $1.438M | |
| % Of Pretax Income | |||
| Net Earnings | -$24.88M | -$16.64M | -$21.61M |
| YoY Change | 138.93% | -38.64% | 24.45% |
| Net Earnings / Revenue | -276.72% | -321.63% | -317.11% |
| Basic Earnings Per Share | |||
| Diluted Earnings Per Share | -$564.3K | -$371.3K | -$498.2K |
| COMMON SHARES | |||
| Basic Shares Outstanding | 56.68M shares | ||
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2018 Q4 | 2018 Q3 | 2018 Q2 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $83.10M | $125.1M | $137.4M |
| YoY Change | -36.56% | -19.91% | -18.12% |
| Cash & Equivalents | $65.51M | $95.87M | $116.8M |
| Short-Term Investments | $17.60M | $29.20M | $38.80M |
| Other Short-Term Assets | $19.80M | $14.40M | $14.70M |
| YoY Change | -54.59% | 23.08% | 13.95% |
| Inventory | $678.0K | $674.0K | $300.0K |
| Prepaid Expenses | |||
| Receivables | $5.498M | $5.431M | $5.300M |
| Other Receivables | $2.100M | $13.90M | $13.80M |
| Total Short-Term Assets | $111.2M | $159.5M | $171.5M |
| YoY Change | -39.29% | -13.35% | -9.82% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $12.02M | $14.64M | $2.532M |
| YoY Change | 68.9% | 510.85% | -65.45% |
| Goodwill | $18.65M | ||
| YoY Change | 0.0% | ||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | $0.00 | $0.00 | $600.0K |
| YoY Change | -100.0% | 100.0% | |
| Other Assets | $276.0K | $821.0K | $18.40M |
| YoY Change | 6.98% | 137.28% | 12.88% |
| Total Long-Term Assets | $29.79M | $65.40M | $65.40M |
| YoY Change | -52.55% | 7.21% | 9.69% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $111.2M | $159.5M | $171.5M |
| Total Long-Term Assets | $29.79M | $65.40M | $65.40M |
| Total Assets | $141.0M | $224.9M | $236.9M |
| YoY Change | -42.67% | -8.23% | -5.16% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $34.20M | $37.50M | $38.20M |
| YoY Change | 23.91% | 17.19% | 52.8% |
| Accrued Expenses | $16.36M | $20.37M | $17.51M |
| YoY Change | -7.21% | 22.33% | 41.51% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | $19.10M | $19.70M | $10.60M |
| YoY Change | 44.7% | 51.54% | 70.97% |
| Total Short-Term Liabilities | $55.61M | $70.78M | $62.20M |
| YoY Change | -22.15% | 3.43% | 16.26% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $60.40M | $64.50M | $73.50M |
| YoY Change | 22.52% | 27.22% | 80.59% |
| Other Long-Term Liabilities | $5.211M | $4.961M | $5.000M |
| YoY Change | 9.96% | 4.75% | -0.52% |
| Total Long-Term Liabilities | $5.211M | $4.961M | $78.50M |
| YoY Change | 9.96% | 4.75% | 1461.88% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $55.61M | $70.78M | $62.20M |
| Total Long-Term Liabilities | $5.211M | $4.961M | $78.50M |
| Total Liabilities | $121.3M | $140.3M | $192.9M |
| YoY Change | -3.35% | 13.29% | 94.4% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$396.3M | -$371.4M | -$354.8M |
| YoY Change | 26.96% | 23.09% | 29.19% |
| Common Stock | $58.00K | $56.00K | $54.00K |
| YoY Change | 13.73% | 9.8% | -93.25% |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $1.852M | $37.77M | $43.93M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $141.0M | $224.9M | $236.9M |
| YoY Change | -42.67% | -8.23% | -5.2% |
Cashflow Statement
| Concept | 2018 Q4 | 2018 Q3 | 2018 Q2 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$24.88M | -$16.64M | -$21.61M |
| YoY Change | 138.93% | -38.64% | 24.45% |
| Depreciation, Depletion And Amortization | $740.0K | $550.0K | $440.0K |
| YoY Change | -161.67% | 175.0% | 144.44% |
| Cash From Operating Activities | -$22.16M | -$24.76M | -$24.09M |
| YoY Change | 6.18% | -1.28% | 0.88% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | -$1.540M | -$2.130M | -$3.840M |
| YoY Change | -48.84% | 287.27% | 1921.05% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $15.06M | $11.47M | $1.660M |
| YoY Change | 71.33% | -147.22% | -108.29% |
| Cash From Investing Activities | $13.52M | $9.330M | -$2.190M |
| YoY Change | 133.91% | -137.58% | -89.17% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | -1.690M | 9.960M | 2.720M |
| YoY Change | -108.18% | -41.89% | -95.0% |
| NET CHANGE | |||
| Cash From Operating Activities | -22.16M | -24.76M | -24.09M |
| Cash From Investing Activities | 13.52M | 9.330M | -2.190M |
| Cash From Financing Activities | -1.690M | 9.960M | 2.720M |
| Net Change In Cash | -10.33M | -5.470M | -23.56M |
| YoY Change | -285.46% | -83.31% | -328.52% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$22.16M | -$24.76M | -$24.09M |
| Capital Expenditures | -$1.540M | -$2.130M | -$3.840M |
| Free Cash Flow | -$20.62M | -$22.63M | -$20.25M |
| YoY Change | 15.45% | -7.75% | -14.52% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| fbio |
Annual Management Services Agreement Fee Incomeexpense
AnnualManagementServicesAgreementFeeIncomeexpense
|
0 | USD | |
| fbio |
Annual Consulting Fee Payable Effective Date
AnnualConsultingFeePayableEffectiveDate
|
2015-02-17 | ||
| CY2018Q3 | us-gaap |
Brokerage Commissions Revenue
BrokerageCommissionsRevenue
|
28397000 | USD |
| us-gaap |
Brokerage Commissions Revenue
BrokerageCommissionsRevenue
|
85422000 | USD | |
| CY2018Q3 | us-gaap |
Underwriting Income Loss
UnderwritingIncomeLoss
|
2534000 | USD |
| us-gaap |
Underwriting Income Loss
UnderwritingIncomeLoss
|
12127000 | USD | |
| CY2018Q3 | fbio |
Private Placement Revenue
PrivatePlacementRevenue
|
13567000 | USD |
| fbio |
Private Placement Revenue
PrivatePlacementRevenue
|
26866000 | USD | |
| CY2018Q3 | fbio |
Return Reserve
ReturnReserve
|
500000 | USD |
| CY2017Q3 | fbio |
Return Reserve
ReturnReserve
|
300000 | USD |
| fbio |
Revenue From Contracts With Customers Excluding Other Revenue
RevenueFromContractsWithCustomersExcludingOtherRevenue
|
131633000 | USD | |
| CY2018Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
95867000 | USD |
| CY2017Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
113915000 | USD |
| CY2018Q3 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
5431000 | USD |
| CY2017Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
7758000 | USD |
| CY2018Q3 | us-gaap |
Short Term Investments
ShortTermInvestments
|
22538000 | USD |
| CY2017Q4 | us-gaap |
Short Term Investments
ShortTermInvestments
|
36002000 | USD |
| CY2018Q3 | us-gaap |
Deposits With Clearing Organizations And Others Securities
DepositsWithClearingOrganizationsAndOthersSecurities
|
336000 | USD |
| CY2017Q4 | us-gaap |
Deposits With Clearing Organizations And Others Securities
DepositsWithClearingOrganizationsAndOthersSecurities
|
1041000 | USD |
| CY2018Q3 | us-gaap |
Receivables From Brokers Dealers And Clearing Organizations
ReceivablesFromBrokersDealersAndClearingOrganizations
|
11884000 | USD |
| CY2017Q4 | us-gaap |
Receivables From Brokers Dealers And Clearing Organizations
ReceivablesFromBrokersDealersAndClearingOrganizations
|
7395000 | USD |
| CY2018Q3 | us-gaap |
Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
|
1610000 | USD |
| CY2017Q4 | us-gaap |
Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
|
1616000 | USD |
| CY2018Q3 | us-gaap |
Investment Owned At Fair Value
InvestmentOwnedAtFairValue
|
6675000 | USD |
| CY2017Q4 | us-gaap |
Investment Owned At Fair Value
InvestmentOwnedAtFairValue
|
1985000 | USD |
| CY2018Q3 | us-gaap |
Inventory Net
InventoryNet
|
674000 | USD |
| CY2017Q4 | us-gaap |
Inventory Net
InventoryNet
|
171000 | USD |
| CY2018Q3 | us-gaap |
Due From Other Related Parties Current
DueFromOtherRelatedPartiesCurrent
|
414000 | USD |
| CY2017Q4 | us-gaap |
Due From Other Related Parties Current
DueFromOtherRelatedPartiesCurrent
|
618000 | USD |
| CY2018Q3 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
14089000 | USD |
| CY2017Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
12680000 | USD |
| CY2018Q3 | us-gaap |
Assets Current
AssetsCurrent
|
159518000 | USD |
| CY2017Q4 | us-gaap |
Assets Current
AssetsCurrent
|
183181000 | USD |
| CY2018Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
14642000 | USD |
| CY2017Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
9513000 | USD |
| CY2018Q3 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
17358000 | USD |
| CY2017Q4 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
17387000 | USD |
| CY2017Q4 | us-gaap |
Long Term Investments
LongTermInvestments
|
1390000 | USD |
| CY2018Q3 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
13935000 | USD |
| CY2017Q4 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
15223000 | USD |
| CY2018Q3 | us-gaap |
Goodwill
Goodwill
|
18645000 | USD |
| CY2017Q4 | us-gaap |
Goodwill
Goodwill
|
18645000 | USD |
| CY2018Q3 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
821000 | USD |
| CY2017Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
611000 | USD |
| CY2018Q3 | us-gaap |
Assets
Assets
|
224919000 | USD |
| CY2017Q4 | us-gaap |
Assets
Assets
|
245950000 | USD |
| CY2018Q3 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
37345000 | USD |
| CY2017Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
36127000 | USD |
| CY2018Q3 | us-gaap |
Due To Related Parties Current
DueToRelatedPartiesCurrent
|
153000 | USD |
| CY2017Q4 | us-gaap |
Due To Related Parties Current
DueToRelatedPartiesCurrent
|
222000 | USD |
| CY2017Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-312127000 | USD |
| CY2018Q3 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
11974000 | USD |
| CY2017Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
10065000 | USD |
| CY2018Q3 | us-gaap |
Financial Instruments Sold Not Yet Purchased At Fair Value
FinancialInstrumentsSoldNotYetPurchasedAtFairValue
|
24000 | USD |
| CY2017Q4 | us-gaap |
Financial Instruments Sold Not Yet Purchased At Fair Value
FinancialInstrumentsSoldNotYetPurchasedAtFairValue
|
151000 | USD |
| CY2017Q4 | fbio |
Warrants Issuable Current
WarrantsIssuableCurrent
|
5597000 | USD |
| CY2018Q3 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
613000 | USD |
| CY2017Q4 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
887000 | USD |
| CY2018Q3 | fbio |
Due To Related Parties Interest Expenses Current
DueToRelatedPartiesInterestExpensesCurrent
|
94000 | USD |
| CY2017Q4 | fbio |
Due To Related Parties Interest Expenses Current
DueToRelatedPartiesInterestExpensesCurrent
|
97000 | USD |
| CY2018Q3 | us-gaap |
Other Notes Payable Current
OtherNotesPayableCurrent
|
9054000 | USD |
| CY2017Q4 | us-gaap |
Other Notes Payable Current
OtherNotesPayableCurrent
|
8528000 | USD |
| CY2018Q3 | us-gaap |
Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
|
10657000 | USD |
| CY2017Q4 | us-gaap |
Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
|
4700000 | USD |
| CY2018Q3 | us-gaap |
Deferred Revenue
DeferredRevenue
|
155000 | USD |
| CY2017Q4 | us-gaap |
Derivative Liabilities Current
DerivativeLiabilitiesCurrent
|
87000 | USD |
| CY2018Q3 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
77000 | USD |
| CY2017Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
181000 | USD |
| CY2018Q3 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
70775000 | USD |
| CY2017Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
67428000 | USD |
| CY2018Q3 | us-gaap |
Long Term Notes Payable
LongTermNotesPayable
|
64546000 | USD |
| CY2017Q4 | us-gaap |
Long Term Notes Payable
LongTermNotesPayable
|
43222000 | USD |
| CY2017Q4 | us-gaap |
Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
|
10059000 | USD |
| CY2018Q3 | us-gaap |
Liabilities
Liabilities
|
140282000 | USD |
| CY2017Q4 | us-gaap |
Liabilities
Liabilities
|
125448000 | USD |
| CY2018Q3 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
1000 | USD |
| CY2017Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
1000 | USD |
| CY2018Q3 | us-gaap |
Common Stock Value
CommonStockValue
|
56000 | USD |
| CY2017Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
51000 | USD |
| CY2018Q3 | us-gaap |
Common Stock Shares Subscriptions
CommonStockSharesSubscriptions
|
495000 | USD |
| CY2017Q4 | us-gaap |
Common Stock Shares Subscriptions
CommonStockSharesSubscriptions
|
500000 | USD |
| CY2018Q3 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
408615000 | USD |
| CY2017Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
364148000 | USD |
| CY2018Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-371394000 | USD |
| CY2018Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
37773000 | USD |
| CY2017Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
52573000 | USD |
| CY2018Q3 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
84637000 | USD |
| CY2017Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
120502000 | USD |
| CY2018Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
224919000 | USD |
| CY2017Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
245950000 | USD |
| CY2018Q3 | us-gaap |
Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
|
447000 | USD |
| CY2017Q4 | us-gaap |
Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
|
973000 | USD |
| CY2018Q3 | us-gaap |
Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
|
445000 | USD |
| CY2017Q4 | us-gaap |
Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
|
62000 | USD |
| CY2018Q3 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2018Q3 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
15000000 | shares |
| CY2018Q3 | fbio |
Preferred Stock Shares Designated
PreferredStockSharesDesignated
|
5000000 | shares |
| CY2018Q3 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
1000000 | shares |
| CY2017Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2017Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
15000000 | shares |
| CY2017Q4 | fbio |
Preferred Stock Shares Designated
PreferredStockSharesDesignated
|
5000000 | shares |
| CY2017Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
1000000 | shares |
| CY2018Q3 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
1000000 | shares |
| CY2017Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
1000000 | shares |
| CY2018Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2018Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
| CY2018Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
56183480 | shares |
| CY2017Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
50991285 | shares |
| CY2018Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
56183480 | shares |
| CY2017Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
50991285 | shares |
| CY2017Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2017Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
| CY2018Q3 | us-gaap |
Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
|
347684 | shares |
| CY2017Q4 | us-gaap |
Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
|
158015 | shares |
| CY2018Q3 | fbio |
Revenue From Contracts With Customers Including Other Revenue
RevenueFromContractsWithCustomersIncludingOtherRevenue
|
58520000 | USD |
| fbio |
Revenue From Contracts With Customers Including Other Revenue
RevenueFromContractsWithCustomersIncludingOtherRevenue
|
165061000 | USD | |
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Use of Estimates</div></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company’s unaudited condensed consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived and intangible assets, fair value measurements, stock-based compensation, common stock issued to acquire licenses, investments, accrued expenses, derivative warrant liabilities, revenue with customers, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | ||
| CY2018Q3 | us-gaap |
Revenues
Revenues
|
63693000 | USD |
| CY2017Q3 | us-gaap |
Revenues
Revenues
|
46886000 | USD |
| us-gaap |
Revenues
Revenues
|
182952000 | USD | |
| us-gaap |
Revenues
Revenues
|
142265000 | USD | |
| CY2018Q3 | fbio |
Revenue From Contracts With Customers Excluding Other Revenue
RevenueFromContractsWithCustomersExcludingOtherRevenue
|
49413000 | USD |
| us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
|
13648000 | USD | |
| us-gaap |
Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
|
0 | USD | |
| us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
128000 | USD | |
| fbio |
Adjustments To Additional Paid In Capital Stock Issued For License Expenses
AdjustmentsToAdditionalPaidInCapitalStockIssuedForLicenseExpenses
|
229000 | USD | |
| us-gaap |
Adjustments To Additional Paid In Capital Income Tax Deficiency From Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation
|
-82000 | USD | |
| fbio |
Adjustments To Additional Paid In Capital Subsidiary Public Offering
AdjustmentsToAdditionalPaidInCapitalSubsidiaryPublicOffering
|
22668000 | USD | |
| fbio |
Stock Issued During Period Value Cash Less Exercise Of Warrants
StockIssuedDuringPeriodValueCashLessExerciseOfWarrants
|
186000 | USD | |
| fbio |
Issuance Of Common Stock For At Market Offering
IssuanceOfCommonStockForAtMarketOffering
|
6959000 | USD | |
| fbio |
Adjustments To Additional Paid In Capital At Market Offering Costs
AdjustmentsToAdditionalPaidInCapitalAtMarketOfferingCosts
|
-240000 | USD | |
| fbio |
Common Shares Issuable For Interest Expenses
CommonSharesIssuableForInterestExpenses
|
495000 | USD | |
| fbio |
Common Shares Issued For Interest Expenses
CommonSharesIssuedForInterestExpenses
|
978000 | USD | |
| us-gaap |
Dividends Preferred Stock
DividendsPreferredStock
|
1758000 | USD | |
| fbio |
Stock Issued During Period Value Interest Expense
StockIssuedDuringPeriodValueInterestExpense
|
1297000 | USD | |
| fbio |
Adjustments To Additional Paid In Capital Acquisition Of Business
AdjustmentsToAdditionalPaidInCapitalAcquisitionOfBusiness
|
-767000 | USD | |
| us-gaap |
Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
|
13615000 | USD | |
| fbio |
Adjustments To Additional Paid In Capital And Noncontrolling Interest From Subsidiary Equity Issuance
AdjustmentsToAdditionalPaidInCapitalAndNoncontrollingInterestFromSubsidiaryEquityIssuance
|
0 | USD | |
| us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
7931000 | USD | |
| us-gaap |
Depreciation
Depreciation
|
1379000 | USD | |
| us-gaap |
Depreciation
Depreciation
|
819000 | USD | |
| us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
2100000 | USD | |
| us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
1235000 | USD | |
| us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
624000 | USD | |
| us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
1316000 | USD | |
| us-gaap |
Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
|
433000 | USD | |
| us-gaap |
Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
|
401000 | USD | |
| fbio |
Amortization Of Forgivable Loans To Registered Representatives
AmortizationOfForgivableLoansToRegisteredRepresentatives
|
474000 | USD | |
| fbio |
Amortization Of Forgivable Loans To Registered Representatives
AmortizationOfForgivableLoansToRegisteredRepresentatives
|
520000 | USD | |
| fbio |
Amortization Of Deferred Clearing Credit
AmortizationOfDeferredClearingCredit
|
-157000 | USD | |
| fbio |
Amortization Of Deferred Clearing Credit
AmortizationOfDeferredClearingCredit
|
-157000 | USD | |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
13658000 | USD | |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
12048000 | USD | |
| us-gaap |
Allowance For Doubtful Accounts Receivable Recoveries
AllowanceForDoubtfulAccountsReceivableRecoveries
|
-18000 | USD | |
| us-gaap |
Allowance For Doubtful Accounts Receivable Recoveries
AllowanceForDoubtfulAccountsReceivableRecoveries
|
274000 | USD | |
| CY2018Q1 | fbio |
National Investment Banking Expenses
NationalInvestmentBankingExpenses
|
100000 | USD |
| CY2018Q2 | us-gaap |
Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
|
500000 | USD |
| CY2017Q2 | us-gaap |
Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
|
500000 | USD |
| CY2018Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
88582000 | USD |
| CY2017Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
79489000 | USD |
| us-gaap |
Operating Expenses
OperatingExpenses
|
267924000 | USD | |
| us-gaap |
Operating Expenses
OperatingExpenses
|
215638000 | USD | |
| CY2018Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-24889000 | USD |
| CY2017Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-32603000 | USD |
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-84972000 | USD | |
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-73373000 | USD | |
| CY2018Q3 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
269000 | USD |
| CY2017Q3 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
204000 | USD |
| us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
841000 | USD | |
| us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
530000 | USD | |
| CY2018Q3 | fbio |
Interestexpenseandfinancefees
Interestexpenseandfinancefees
|
2228000 | USD |
| CY2017Q3 | fbio |
Interestexpenseandfinancefees
Interestexpenseandfinancefees
|
3220000 | USD |
| fbio |
Interestexpenseandfinancefees
Interestexpenseandfinancefees
|
6455000 | USD | |
| fbio |
Interestexpenseandfinancefees
Interestexpenseandfinancefees
|
5298000 | USD | |
| CY2018Q3 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
0 | USD |
| CY2017Q3 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
639000 | USD |
| us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-5155000 | USD | |
| CY2018Q3 | fbio |
Changeinfairvalueofsubsidiaryconvertiblenote
Changeinfairvalueofsubsidiaryconvertiblenote
|
-84000 | USD |
| CY2017Q3 | fbio |
Changeinfairvalueofsubsidiaryconvertiblenote
Changeinfairvalueofsubsidiaryconvertiblenote
|
-74000 | USD |
| fbio |
Changeinfairvalueofsubsidiaryconvertiblenote
Changeinfairvalueofsubsidiaryconvertiblenote
|
26000 | USD | |
| fbio |
Changeinfairvalueofsubsidiaryconvertiblenote
Changeinfairvalueofsubsidiaryconvertiblenote
|
-359000 | USD | |
| CY2018Q3 | fbio |
Change In Fair Value Of Short Term Investments
ChangeInFairValueOfShortTermInvestments
|
-565000 | USD |
| CY2017Q3 | fbio |
Change In Fair Value Of Short Term Investments
ChangeInFairValueOfShortTermInvestments
|
270000 | USD |
| fbio |
Change In Fair Value Of Short Term Investments
ChangeInFairValueOfShortTermInvestments
|
-1390000 | USD | |
| fbio |
Change In Fair Value Of Short Term Investments
ChangeInFairValueOfShortTermInvestments
|
-241000 | USD | |
| CY2018Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
44818186 | shares |
| CY2017Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
40724115 | shares |
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
43578763 | shares | |
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
40547364 | shares | |
| fbio |
Change In Fair Value Of Contingently Issuable Warrants
ChangeInFairValueOfContingentlyIssuableWarrants
|
7931000 | USD | |
| fbio |
Change In Fair Value Of Contingently Issuable Warrants
ChangeInFairValueOfContingentlyIssuableWarrants
|
-5155000 | USD | |
| us-gaap |
Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
|
3804000 | USD | |
| us-gaap |
Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
|
3394000 | USD | |
| fbio |
Change In Fair Value Of Subsidiaries Assets And Liabilities
ChangeInFairValueOfSubsidiariesAssetsAndLiabilities
|
18000 | USD | |
| fbio |
Change In Fair Value Of Subsidiaries Assets And Liabilities
ChangeInFairValueOfSubsidiariesAssetsAndLiabilities
|
1341000 | USD | |
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-2327000 | USD | |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
6828000 | USD | |
| CY2018Q3 | us-gaap |
Other Nonoperating Expense
OtherNonoperatingExpense
|
146000 | USD |
| CY2017Q3 | us-gaap |
Other Nonoperating Expense
OtherNonoperatingExpense
|
245000 | USD |
| us-gaap |
Other Nonoperating Expense
OtherNonoperatingExpense
|
258000 | USD | |
| us-gaap |
Other Nonoperating Expense
OtherNonoperatingExpense
|
232000 | USD | |
| CY2018Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-2754000 | USD |
| CY2017Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-3704000 | USD |
| us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-15167000 | USD | |
| us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-445000 | USD | |
| CY2018Q3 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-27643000 | USD |
| CY2017Q3 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-36307000 | USD |
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-100139000 | USD | |
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-73818000 | USD | |
| CY2018Q3 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
944000 | USD |
| CY2017Q3 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | USD |
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
2382000 | USD | |
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | USD | |
| CY2018Q3 | us-gaap |
Profit Loss
ProfitLoss
|
-28587000 | USD |
| CY2017Q3 | us-gaap |
Profit Loss
ProfitLoss
|
-36307000 | USD |
| us-gaap |
Profit Loss
ProfitLoss
|
-102521000 | USD | |
| us-gaap |
Profit Loss
ProfitLoss
|
-73818000 | USD | |
| CY2018Q3 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-11949000 | USD |
| CY2017Q3 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-9191000 | USD |
| us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-43254000 | USD | |
| us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-17355000 | USD | |
| CY2018Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-16638000 | USD |
| CY2017Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-27116000 | USD |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-59267000 | USD | |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-56463000 | USD | |
| CY2018Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.37 | |
| CY2017Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.67 | |
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.36 | ||
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.39 | ||
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
3752000 | USD | |
| us-gaap |
Increase Decrease In Broker Dealer Related Receivables Payables Net
IncreaseDecreaseInBrokerDealerRelatedReceivablesPayablesNet
|
4489000 | USD | |
| us-gaap |
Increase Decrease In Broker Dealer Related Receivables Payables Net
IncreaseDecreaseInBrokerDealerRelatedReceivablesPayablesNet
|
4925000 | USD | |
| us-gaap |
Increase Decrease In Other Loans
IncreaseDecreaseInOtherLoans
|
468000 | USD | |
| us-gaap |
Increase Decrease In Other Loans
IncreaseDecreaseInOtherLoans
|
77000 | USD | |
| us-gaap |
Increase Decrease In Marketable Securities Restricted
IncreaseDecreaseInMarketableSecuritiesRestricted
|
4690000 | USD | |
| us-gaap |
Increase Decrease In Marketable Securities Restricted
IncreaseDecreaseInMarketableSecuritiesRestricted
|
-762000 | USD | |
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
503000 | USD | |
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
115000 | USD | |
| us-gaap |
Increase Decrease Due From Other Related Parties
IncreaseDecreaseDueFromOtherRelatedParties
|
-204000 | USD | |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
999000 | USD | |
| us-gaap |
Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
|
47538000 | USD | |
| us-gaap |
Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
|
44088000 | USD | |
| us-gaap |
Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
|
61002000 | USD | |
| us-gaap |
Payments For Mortgage Deposits
PaymentsForMortgageDeposits
|
344000 | USD | |
| us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-980000 | USD | |
| us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
4195000 | USD | |
| us-gaap |
Increase Decrease In Financial Instruments Sold Not Yet Purchased
IncreaseDecreaseInFinancialInstrumentsSoldNotYetPurchased
|
-127000 | USD | |
| us-gaap |
Increase Decrease In Financial Instruments Sold Not Yet Purchased
IncreaseDecreaseInFinancialInstrumentsSoldNotYetPurchased
|
-298000 | USD | |
| us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
155000 | USD | |
| us-gaap |
Increase Decrease Due From Other Related Parties
IncreaseDecreaseDueFromOtherRelatedParties
|
-1152000 | USD | |
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
562000 | USD | |
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
1426000 | USD | |
| us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
680000 | USD | |
| us-gaap |
Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
|
-274000 | USD | |
| us-gaap |
Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
|
22000 | USD | |
| us-gaap |
Increase Decrease In Due To Other Related Parties Current
IncreaseDecreaseInDueToOtherRelatedPartiesCurrent
|
-3000 | USD | |
| us-gaap |
Increase Decrease In Due To Other Related Parties Current
IncreaseDecreaseInDueToOtherRelatedPartiesCurrent
|
430000 | USD | |
| us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
222000 | USD | |
| us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
-288000 | USD | |
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-77835000 | USD | |
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-60444000 | USD | |
| fbio |
Payment For Research And Development Licenses
PaymentForResearchAndDevelopmentLicenses
|
1075000 | USD | |
| fbio |
Payment For Research And Development Licenses
PaymentForResearchAndDevelopmentLicenses
|
965000 | USD | |
| us-gaap |
Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
|
2000 | USD | |
| us-gaap |
Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
|
2000 | USD | |
| us-gaap |
Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
|
0 | USD | |
| us-gaap |
Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
|
750000 | USD | |
| fbio |
Convertible Notes Conversion Converted Instrument Amount
ConvertibleNotesConversionConvertedInstrumentAmount
|
0 | USD | |
| us-gaap |
Proceeds From Other Deposits
ProceedsFromOtherDeposits
|
42000 | USD | |
| us-gaap |
Payments For Proceeds From Businesses And Interest In Affiliates
PaymentsForProceedsFromBusinessesAndInterestInAffiliates
|
187000 | USD | |
| us-gaap |
Payments For Proceeds From Businesses And Interest In Affiliates
PaymentsForProceedsFromBusinessesAndInterestInAffiliates
|
19000 | USD | |
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
5054000 | USD | |
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-46001000 | USD | |
| us-gaap |
Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
|
1297000 | USD | |
| us-gaap |
Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
|
0 | USD | |
| us-gaap |
Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
|
1758000 | USD | |
| us-gaap |
Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
|
4076000 | USD | |
| us-gaap |
Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
|
0 | USD | |
| us-gaap |
Proceeds From Unsecured Lines Of Credit
ProceedsFromUnsecuredLinesOfCredit
|
0 | USD | |
| us-gaap |
Proceeds From Unsecured Lines Of Credit
ProceedsFromUnsecuredLinesOfCredit
|
2500000 | USD | |
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
53999000 | USD | |
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
129723000 | USD | |
| us-gaap |
Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
|
0 | USD | |
| fbio |
Proceeds From Issuance Of At Market Offering
ProceedsFromIssuanceOfAtMarketOffering
|
6959000 | USD | |
| fbio |
Proceeds From Issuance Of At Market Offering
ProceedsFromIssuanceOfAtMarketOffering
|
0 | USD | |
| fbio |
Payment Of Cost Related To Atthemarket Offering
PaymentOfCostRelatedToAtthemarketOffering
|
240000 | USD | |
| fbio |
Payment Of Cost Related To Atthemarket Offering
PaymentOfCostRelatedToAtthemarketOffering
|
0 | USD | |
| us-gaap |
Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
|
23011000 | USD | |
| us-gaap |
Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
|
104034000 | USD | |
| us-gaap |
Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
|
343000 | USD | |
| us-gaap |
Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
|
9389000 | USD | |
| us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
186000 | USD | |
| us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
0 | USD | |
| us-gaap |
Proceeds From Unsecured Notes Payable
ProceedsFromUnsecuredNotesPayable
|
0 | USD | |
| us-gaap |
Proceeds From Unsecured Notes Payable
ProceedsFromUnsecuredNotesPayable
|
28355000 | USD | |
| us-gaap |
Payments Of Financing Costs
PaymentsOfFinancingCosts
|
404000 | USD | |
| us-gaap |
Payments Of Financing Costs
PaymentsOfFinancingCosts
|
1081000 | USD | |
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
0 | USD | |
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
27000 | USD | |
| fbio |
Proceeds From Issuance Of Common Stock Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockEmployeeStockPurchasePlan
|
128000 | USD | |
| fbio |
Proceeds From Issuance Of Common Stock Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockEmployeeStockPurchasePlan
|
42000 | USD | |
| us-gaap |
Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
|
82000 | USD | |
| us-gaap |
Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
|
0 | USD | |
| us-gaap |
Proceeds From Other Debt
ProceedsFromOtherDebt
|
21707000 | USD | |
| us-gaap |
Proceeds From Other Debt
ProceedsFromOtherDebt
|
0 | USD | |
| us-gaap |
Repayments Of Other Debt
RepaymentsOfOtherDebt
|
132000 | USD | |
| us-gaap |
Repayments Of Other Debt
RepaymentsOfOtherDebt
|
0 | USD | |
| fbio |
Payment Of Debt Issuance Costs Associated With Subsidiary Convertible Notes
PaymentOfDebtIssuanceCostsAssociatedWithSubsidiaryConvertibleNotes
|
0 | USD | |
| fbio |
Payment Of Debt Issuance Costs Associated With Subsidiary Convertible Notes
PaymentOfDebtIssuanceCostsAssociatedWithSubsidiaryConvertibleNotes
|
1071000 | USD | |
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-18782000 | USD | |
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
23278000 | USD | |
| CY2017Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
132343000 | USD |
| CY2016Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
105184000 | USD |
| CY2018Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
113561000 | USD |
| CY2017Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
128462000 | USD |
| fbio |
Convertible Notes Conversion Converted Instrument Amount
ConvertibleNotesConversionConvertedInstrumentAmount
|
201000 | USD | |
| fbio |
Unpaid Debt Offering Cost
UnpaidDebtOfferingCost
|
0 | USD | |
| fbio |
Unpaid Debt Offering Cost
UnpaidDebtOfferingCost
|
42000 | USD | |
| fbio |
Issue Of Common Stock For Acquiring License Value
IssueOfCommonStockForAcquiringLicenseValue
|
0 | USD | |
| fbio |
Issue Of Common Stock For Acquiring License Value
IssueOfCommonStockForAcquiringLicenseValue
|
1682000 | USD | |
| us-gaap |
Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
|
0 | USD | |
| us-gaap |
Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
|
314000 | USD | |
| fbio |
Noncash Or Part Noncash Acquisition Fixed Assets Acquired Payable
NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredPayable
|
537000 | USD | |
| fbio |
Noncash Or Part Noncash Acquisition Fixed Assets Acquired Payable
NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredPayable
|
665000 | USD | |
| us-gaap |
Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
|
187000 | USD | |
| CY2018Q3 | fbio |
Employee Stock Purchase Plan Offering Fair Value Reckoning Percentage
EmployeeStockPurchasePlanOfferingFairValueReckoningPercentage
|
0.85 | pure |
| CY2018Q3 | fbio |
Employee Stock Purchase Plan Compensation Expense Recognized
EmployeeStockPurchasePlanCompensationExpenseRecognized
|
52000 | USD |
| CY2017Q3 | fbio |
Employee Stock Purchase Plan Compensation Expense Recognized
EmployeeStockPurchasePlanCompensationExpenseRecognized
|
52000 | USD |
| us-gaap |
Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
|
19000 | USD | |
| fbio |
Reclassification Of Warrant Liability From Debt To Equity
ReclassificationOfWarrantLiabilityFromDebtToEquity
|
13615000 | USD | |
| fbio |
Reclassification Of Warrant Liability From Debt To Equity
ReclassificationOfWarrantLiabilityFromDebtToEquity
|
0 | USD | |
| us-gaap |
Interest Paid Net
InterestPaidNet
|
13000 | USD | |
| us-gaap |
Interest Paid Net
InterestPaidNet
|
11000 | USD | |
| CY2018Q2 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
3494000 | USD |
| CY2017Q3 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
2872000 | USD |
| CY2018Q2 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
962000 | USD |
| CY2017Q3 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
475000 | USD |
| CY2018Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
2532000 | USD |
| CY2017Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
2397000 | USD |
| CY2018Q3 | us-gaap |
Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
|
10657000 | USD |
| CY2017Q4 | us-gaap |
Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
|
1390000 | USD |
| CY2017Q4 | us-gaap |
Assets Fair Value Disclosure
AssetsFairValueDisclosure
|
1390000 | USD |
| CY2017Q4 | us-gaap |
Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
|
14846000 | USD |
| CY2017Q4 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
|
21833000 | USD |
| us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
|
-4076000 | USD | |
| us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
|
-13615000 | USD | |
| us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
|
1390000 | USD | |
| us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
|
-26000 | USD | |
| fbio |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Derivative Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisDerivativeLiabilityGainLossIncludedInEarnings
|
-7931000 | USD | |
| CY2018Q3 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
|
10657000 | USD |
| CY2018Q3 | fbio |
Working Capital Note Convertible To Equity
WorkingCapitalNoteConvertibleToEquity
|
0 | USD |
| fbio |
Issuance Of Warrants In Connection With2017 Subordinated Note Financing
IssuanceOfWarrantsInConnectionWith2017SubordinatedNoteFinancing
|
0 | USD | |
| fbio |
Issuance Of Warrants In Connection With2017 Subordinated Note Financing
IssuanceOfWarrantsInConnectionWith2017SubordinatedNoteFinancing
|
1784000 | USD | |
| CY2018Q2 | us-gaap |
Loss Contingency Accrual Carrying Value Current
LossContingencyAccrualCarryingValueCurrent
|
500000 | USD |
| CY2017Q3 | us-gaap |
Loss Contingency Accrual Carrying Value Current
LossContingencyAccrualCarryingValueCurrent
|
2400000 | USD |
| CY2018Q2 | us-gaap |
Loss Contingency Accrual Provision
LossContingencyAccrualProvision
|
-100000 | USD |
| CY2017Q2 | us-gaap |
Loss Contingency Accrual Provision
LossContingencyAccrualProvision
|
2300000 | USD |
| us-gaap |
Loss Contingency Accrual Provision
LossContingencyAccrualProvision
|
600000 | USD | |
| us-gaap |
Loss Contingency Accrual Provision
LossContingencyAccrualProvision
|
3300000 | USD | |
| CY2018Q3 | us-gaap |
Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
|
3300000 | USD |
| CY2018Q2 | us-gaap |
Legal Fees
LegalFees
|
400000 | USD |
| CY2017Q2 | us-gaap |
Legal Fees
LegalFees
|
400000 | USD |
| us-gaap |
Legal Fees
LegalFees
|
700000 | USD | |
| us-gaap |
Legal Fees
LegalFees
|
1200000 | USD | |
| fbio |
Lease Sharing Agreements Contributions To Property Under Lease
LeaseSharingAgreementsContributionsToPropertyUnderLease
|
96000 | USD | |
| CY2018Q3 | fbio |
Administration Fee Payable
AdministrationFeePayable
|
37000 | USD |
| us-gaap |
Noninterest Expense Transfer Agent And Custodian Fees
NoninterestExpenseTransferAgentAndCustodianFees
|
1700000 | USD | |
| CY2018Q3 | us-gaap |
Long Term Investments
LongTermInvestments
|
0 | USD |
| CY2018Q3 | fbio |
Warrants Issuable Current
WarrantsIssuableCurrent
|
0 | USD |
| CY2017Q4 | us-gaap |
Deferred Revenue
DeferredRevenue
|
0 | USD |
| CY2018Q3 | us-gaap |
Derivative Liabilities Current
DerivativeLiabilitiesCurrent
|
0 | USD |
| CY2018Q3 | us-gaap |
Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
|
0 | USD |
| CY2018Q3 | us-gaap |
Preferred Stock Liquidation Preference
PreferredStockLiquidationPreference
|
25.00 | |
| CY2017Q4 | us-gaap |
Preferred Stock Liquidation Preference
PreferredStockLiquidationPreference
|
25.00 | |
| CY2018Q3 | us-gaap |
Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
|
5035000 | USD |
| CY2017Q3 | us-gaap |
Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
|
4313000 | USD |
| us-gaap |
Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
|
13658000 | USD | |
| us-gaap |
Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
|
12048000 | USD | |
| fbio |
Employee Stock Purchase Plan Compensation Expense Recognized
EmployeeStockPurchasePlanCompensationExpenseRecognized
|
100000 | USD | |
| fbio |
Employee Stock Purchase Plan Compensation Expense Recognized
EmployeeStockPurchasePlanCompensationExpenseRecognized
|
100000 | USD | |
| CY2018Q3 | us-gaap |
Long Term Debt
LongTermDebt
|
85149000 | USD |
| CY2017Q4 | us-gaap |
Long Term Debt
LongTermDebt
|
67544000 | USD |
| CY2018Q3 | us-gaap |
Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
|
892000 | USD |
| CY2017Q4 | us-gaap |
Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
|
1035000 | USD |
| CY2018Q3 | us-gaap |
Notes Payable
NotesPayable
|
84257000 | USD |
| CY2017Q4 | us-gaap |
Notes Payable
NotesPayable
|
66509000 | USD |
| CY2018Q3 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
1471000 | USD |
| CY2017Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
1625000 | USD |
| CY2018Q3 | us-gaap |
Accrued Salaries Current
AccruedSalariesCurrent
|
4349000 | USD |
| CY2017Q4 | us-gaap |
Accrued Salaries Current
AccruedSalariesCurrent
|
5279000 | USD |
| CY2018Q3 | fbio |
Accrued Expenses Related Party
AccruedExpensesRelatedParty
|
50000 | USD |
| CY2017Q4 | fbio |
Accrued Expenses Related Party
AccruedExpensesRelatedParty
|
95000 | USD |
| CY2018Q3 | fbio |
Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
|
3036000 | USD |
| CY2017Q4 | fbio |
Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
|
1873000 | USD |
| CY2018Q3 | fbio |
Accrued Expenses Releted To Dr Falk Pharma Milestone
AccruedExpensesReletedToDrFalkPharmaMilestone
|
1300000 | USD |
| CY2017Q4 | fbio |
Accrued Expenses Releted To Dr Falk Pharma Milestone
AccruedExpensesReletedToDrFalkPharmaMilestone
|
3059000 | USD |
| CY2018Q3 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
1045000 | USD |
| CY2017Q4 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
1411000 | USD |
| CY2018Q3 | fbio |
Deferred Coupon Funding
DeferredCouponFunding
|
1490000 | USD |
| CY2017Q4 | fbio |
Deferred Coupon Funding
DeferredCouponFunding
|
1087000 | USD |
| CY2018Q3 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
644000 | USD |
| CY2017Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
1030000 | USD |
| CY2018Q3 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
20369000 | USD |
| CY2017Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
17632000 | USD |
| CY2018Q3 | fbio |
Deferred Rent And Long Term Lease Abandonment Non Current
DeferredRentAndLongTermLeaseAbandonmentNonCurrent
|
4961000 | USD |
| CY2017Q4 | fbio |
Deferred Rent And Long Term Lease Abandonment Non Current
DeferredRentAndLongTermLeaseAbandonmentNonCurrent
|
4739000 | USD |
| CY2018Q3 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
4961000 | USD |
| CY2017Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
4739000 | USD |
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
17667124 | shares | |
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
13063630 | shares | |
| CY2018Q3 | us-gaap |
Interest Expense
InterestExpense
|
2228000 | USD |
| CY2017Q3 | us-gaap |
Interest Expense
InterestExpense
|
3220000 | USD |
| us-gaap |
Interest Expense
InterestExpense
|
6455000 | USD | |
| us-gaap |
Interest Expense
InterestExpense
|
5298000 | USD | |
| us-gaap |
Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
|
90118000 | USD | |
| CY2018Q3 | us-gaap |
Minority Interest
MinorityInterest
|
46864000 | USD |
| CY2017 | us-gaap |
Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
|
100889000 | USD |
| CY2017 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-32960000 | USD |
| CY2017Q4 | us-gaap |
Minority Interest
MinorityInterest
|
67929000 | USD |
| fbio |
Common Shares Issued For Opus Interest Expenses In Value
CommonSharesIssuedForOpusInterestExpensesInValue
|
574000 | USD | |
| fbio |
Adjustments To Additional Paid In Capital Subsidiary At Market Offering
AdjustmentsToAdditionalPaidInCapitalSubsidiaryAtMarketOffering
|
7726000 | USD | |
| fbio |
Adjustments To Additional Paid In Capital Capital Contribution For2017 Bonuses
AdjustmentsToAdditionalPaidInCapitalCapitalContributionFor2017Bonuses
|
1000000 | USD | |
| us-gaap |
Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
|
495000 | USD | |
| us-gaap |
Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
|
353000 | USD | |
| us-gaap |
Paid In Kind Interest
PaidInKindInterest
|
978000 | USD | |
| us-gaap |
Paid In Kind Interest
PaidInKindInterest
|
189000 | USD | |
| fbio |
Common Stock Issued For Services Of Opus Interest Expenses
CommonStockIssuedForServicesOfOpusInterestExpenses
|
-574000 | USD | |
| fbio |
Common Stock Issued For Services Of Opus Interest Expenses
CommonStockIssuedForServicesOfOpusInterestExpenses
|
0 | USD | |
| us-gaap |
Impairment Of Investments
ImpairmentOfInvestments
|
0 | USD | |
| us-gaap |
Impairment Of Investments
ImpairmentOfInvestments
|
250000 | USD | |
| us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-200000 | USD | |
| us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
0 | USD | |
| us-gaap |
Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
|
-19000 | USD | |
| us-gaap |
Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
|
84000 | USD | |
| us-gaap |
Proceeds From Collection Of Notes Receivable
ProceedsFromCollectionOfNotesReceivable
|
69000 | USD | |
| us-gaap |
Proceeds From Collection Of Notes Receivable
ProceedsFromCollectionOfNotesReceivable
|
28000 | USD | |
| fbio |
Payment Of Cost Related To Subsidiaries At The Market Offering
PaymentOfCostRelatedToSubsidiariesAtTheMarketOffering
|
234000 | USD | |
| fbio |
Payment Of Cost Related To Subsidiaries At The Market Offering
PaymentOfCostRelatedToSubsidiariesAtTheMarketOffering
|
0 | USD | |
| fbio |
Payment Of Nsc Note
PaymentOfNscNote
|
0 | USD | |
| fbio |
Payment Of Nsc Note
PaymentOfNscNote
|
3608000 | USD | |
| us-gaap |
Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
|
0 | USD | |
| us-gaap |
Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
|
9914000 | USD | |
| fbio |
Proceeds From Issuance Of Subsidiaries At Market Offering
ProceedsFromIssuanceOfSubsidiariesAtMarketOffering
|
7980000 | USD | |
| fbio |
Proceeds From Issuance Of Subsidiaries At Market Offering
ProceedsFromIssuanceOfSubsidiariesAtMarketOffering
|
0 | USD | |
| fbio |
Unpaid Subsidiarys At Market Offering Cost
UnpaidSubsidiarysAtMarketOfferingCost
|
20000 | USD | |
| fbio |
Unpaid Subsidiarys At Market Offering Cost
UnpaidSubsidiarysAtMarketOfferingCost
|
0 | USD | |
| CY2017Q4 | fbio |
Proceeds From Sale Of Common Stock Gross Percent
ProceedsFromSaleOfCommonStockGrossPercent
|
0.030 | pure |
| CY2018Q3 | us-gaap |
Sale Of Stock Price Per Share
SaleOfStockPricePerShare
|
4.33 | |
| us-gaap |
Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
|
0 | USD | |
| us-gaap |
Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
|
50000 | USD | |
| CY2018Q3 | us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
5168000 | USD |
| us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
17366000 | USD | |
| CY2018Q3 | fbio |
Milestones Related To License Agreement
MilestonesRelatedToLicenseAgreement
|
2500000 | USD |
| us-gaap |
Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
|
P3Y | ||
| CY2018Q3 | fbio |
Common Stock Redemption Price Per Share
CommonStockRedemptionPricePerShare
|
11.00 | |
| CY2018Q3 | fbio |
Accrued Manufacturing Costs
AccruedManufacturingCosts
|
1411000 | USD |
| CY2018Q3 | fbio |
Accrual Clinical Supplies
AccrualClinicalSupplies
|
2619000 | USD |
| CY2018Q3 | fbio |
Accrued License Maintenance Fees
AccruedLicenseMaintenanceFees
|
454000 | USD |
| CY2018Q3 | fbio |
Advisory Revenue
AdvisoryRevenue
|
4915000 | USD |
| fbio |
Advisory Revenue
AdvisoryRevenue
|
7062000 | USD | |
| fbio |
Other Revenue
OtherRevenue
|
156000 | USD | |
| CY2018Q3 | fbio |
Other National Revenue
OtherNationalRevenue
|
9107000 | USD |
| fbio |
Other National Revenue
OtherNationalRevenue
|
33428000 | USD | |
| CY2018Q3 | fbio |
Other Revenue
OtherRevenue
|
0 | USD |
| fbio |
Common Shares Issued For2017 Subordinated Note Financing Interest Expense
CommonSharesIssuedFor2017SubordinatedNoteFinancingInterestExpense
|
500000 | USD | |
| fbio |
Common Shares Issued For2017 Subordinated Note Financing Interest Expense
CommonSharesIssuedFor2017SubordinatedNoteFinancingInterestExpense
|
0 | USD | |
| CY2018Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
86289 | shares |
| CY2018Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
147741 | shares |
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1110501 | shares |
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
3.78 | |
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
|
1351080 | USD |
| CY2017 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P3Y11M12D | |
| us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
0 | shares | |
| us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
0 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
0 | USD | |
| CY2018Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1110501 | shares |
| CY2018Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
3.78 | |
| CY2018Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
|
87132 | USD |
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P3Y2M16D | ||
| CY2018Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
1085501 | shares |
| CY2018Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
|
3.75 | |
| CY2018Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
|
87132 | USD |
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
|
P3Y2M5D | ||
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
7700000 | USD | |
| dei |
Trading Symbol
TradingSymbol
|
FBIO | ||
| CY2018Q4 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
56679505 | shares |
| dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | ||
| dei |
Entity Small Business
EntitySmallBusiness
|
false | ||
| us-gaap |
Proceeds From Other Deposits
ProceedsFromOtherDeposits
|
0 | USD | |
| CY2017Q3 | us-gaap |
Research And Development In Process
ResearchAndDevelopmentInProcess
|
0 | USD |
| CY2017Q4 | fbio |
Accrual Clinical Supplies
AccrualClinicalSupplies
|
85000 | USD |
| CY2017Q4 | fbio |
Accrued License Maintenance Fees
AccruedLicenseMaintenanceFees
|
100000 | USD |
| us-gaap |
Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
|
0 | USD | |
| CY2017Q4 | fbio |
Milestones Related To License Agreement
MilestonesRelatedToLicenseAgreement
|
800000 | USD |
| CY2017Q4 | fbio |
Accrued Manufacturing Costs
AccruedManufacturingCosts
|
1188000 | USD |
| us-gaap |
Business Combination Contingent Consideration Arrangements Description
BusinessCombinationContingentConsiderationArrangementsDescription
|
Fortress contended that no such payment is due because a condition of the EUR 2.5 million payment was the delivery of a Clinical Study Report that addressed the primary and secondary objectives of a Phase II trial, and Fortress contended that Dr. Falk Pharma failed to deliver such a Clinical Study Report. Dr. Falk Pharma filed a lawsuit against Fortress in the above-referenced Court in Frankfurt, Germany to recover the EUR 2.5 million plus interest and attorneys’ fees, and Fortress filed an answer to the complaint, denying that it had any liability to Dr. Falk Pharma. | ||
| fbio |
Description Of Fee Paid
DescriptionOfFeePaid
|
NSC received a fee of approximately $1.8 million, or 8% on the gross proceeds raised of $23.0 million. | ||
| CY2018Q3 | fbio |
Contract Customer Deferred Revenue Liability Current
ContractCustomerDeferredRevenueLiabilityCurrent
|
629000 | USD |
| CY2017Q4 | fbio |
Contract Customer Deferred Revenue Liability Current
ContractCustomerDeferredRevenueLiabilityCurrent
|
786000 | USD |
| us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
45000 | USD | |
| us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
0 | USD | |
| dei |
Document Type
DocumentType
|
10-Q | ||
| dei |
Amendment Flag
AmendmentFlag
|
false | ||
| dei |
Document Period End Date
DocumentPeriodEndDate
|
2018-09-30 | ||
| dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2018 | ||
| dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q3 | ||
| dei |
Entity Registrant Name
EntityRegistrantName
|
Fortress Biotech, Inc. | ||
| dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001429260 | ||
| dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
| dei |
Entity Filer Category
EntityFilerCategory
|
Accelerated Filer | ||
| us-gaap |
Payments For Mortgage Deposits
PaymentsForMortgageDeposits
|
0 | USD |
